Skip to content

Study · Non-randomized trial · 2019

6 results

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.

Bækdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW

Clinical pharmacokinetics1 Sept 2019Cited by 52 (Europe PMC)

PMID30945118 (opens in a new tab)PMCIDPMC6719321 (opens in a new tab)DOI10.1007/s40262-019-00756-2 (opens in a new tab)PepBankPUB-30945118
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy subjects, oral semaglutide had no apparent effect on the AUC or Cmax of lisinopril.

    In plain wordsIn healthy people, oral semaglutide did not change how much lisinopril reached the blood.

    Peptide
    Semaglutide
    Outcome
    No significant changeLisinopril exposure (AUC, Cmax)
    Study

    n: not reported in source

    Comparator
    Co-medication without semaglutide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 mg once daily · oralAs given in this study (human).

    Source sentences

    Summary
    There were no apparent effects of oral semaglutide on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) for lisinopril, warfarin, and digoxin
    2 context sentences
    Summary · context
    Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin.
    Summary · context
    In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state).
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy subjects, oral semaglutide had no apparent effect on the AUC or Cmax of warfarin.

    In plain wordsIn healthy people, oral semaglutide did not change how much warfarin reached the blood.

    Peptide
    Semaglutide
    Outcome
    No significant changeWarfarin exposure (AUC, Cmax)
    Study

    n: not reported in source

    Comparator
    Co-medication without semaglutide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 mg once daily · oralAs given in this study (human).

    Source sentences

    Summary
    There were no apparent effects of oral semaglutide on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) for lisinopril, warfarin, and digoxin
    2 context sentences
    Summary · context
    Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin.
    Summary · context
    In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state).
  3. 03HumanNon-randomized trialPharmacokinetics

    In healthy subjects, oral semaglutide had no apparent effect on the AUC or Cmax of digoxin.

    In plain wordsIn healthy people, oral semaglutide did not change how much digoxin reached the blood.

    Peptide
    Semaglutide
    Outcome
    No significant changeDigoxin exposure (AUC, Cmax)
    Study

    n: not reported in source

    Comparator
    Co-medication without semaglutide
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 mg once daily · oralAs given in this study (human).

    Source sentences

    Summary
    There were no apparent effects of oral semaglutide on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) for lisinopril, warfarin, and digoxin
    2 context sentences
    Summary · context
    Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin.
    Summary · context
    In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state).
  4. 04HumanNon-randomized trialPharmacokinetics

    In healthy subjects, coadministration of oral semaglutide increased metformin AUC by 32% versus metformin alone.

    In plain wordsIn healthy people, oral semaglutide raised metformin exposure by 32% compared with metformin alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseMetformin AUC
    Study

    n: not reported in source

    Comparator
    Metformin alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 mg once daily · oralAs given in this study (human).

    Measurements

    Metformin AUC increase
    32%
    with oral semaglutide

    Source sentences

    Summary
    The AUC of metformin was increased by 32% (90% confidence interval 1.23-1.43) by oral semaglutide coadministration versus metformin alone
    2 context sentences
    Summary · context
    Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin.
    Summary · context
    In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state).
  5. 05HumanNon-randomized trialPharmacokinetics

    In healthy subjects, oral semaglutide coadministration did not change metformin Cmax versus metformin alone.

    In plain wordsIn healthy people, oral semaglutide did not change the peak metformin level compared with metformin alone.

    Peptide
    Semaglutide
    Outcome
    No significant changeMetformin Cmax
    Study

    n: not reported in source

    Comparator
    Metformin alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 mg once daily · oralAs given in this study (human).

    Source sentences

    Summary
    The AUC of metformin was increased by 32% (90% confidence interval 1.23-1.43) by oral semaglutide coadministration versus metformin alone, whereas the Cmax was unaffected.
    2 context sentences
    Summary · context
    Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin.
    Summary · context
    In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state).
  6. 06HumanNon-randomized trialSafety outcome

    In healthy subjects, adverse events during oral semaglutide were in line with those seen before for GLP-1 receptor agonists.

    In plain wordsIn healthy people, side effects of oral semaglutide matched those already known for GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 mg once daily · oralAs given in this study (human).

    Source sentences

    Summary
    Adverse events were in line with those previously observed for GLP-1 receptor agonists.
    2 context sentences
    Summary · context
    Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin.
    Summary · context
    In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT02249910

Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects

Novo Nordisk A/Sn = 3218 Sept 2014 to 6 Mar 2015

Diabetes · Healthy

Trial pageClinicalTrials.govUpdated 17 Feb 2020
CompletedPhase 1NCT02070510

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Novo Nordisk A/Sn = 5227 Feb 2014 to 20 Aug 2014

Diabetes · Healthy

Trial pageClinicalTrials.govUpdated 17 Feb 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.